Clinical Trials Logo

Metabolic Syndrome X clinical trials

View clinical trials related to Metabolic Syndrome X.

Filter by:

NCT ID: NCT01150955 Completed - Obesity Clinical Trials

Potential Beneficial Effects of Resveratrol

Start date: October 2010
Phase: N/A
Study type: Interventional

We want to investigate whether the food supplement resveratrol is able to counteract the detrimental effects of obesity.

NCT ID: NCT01146314 Completed - Type 2 Diabetes Clinical Trials

A Family Based Intervention to Reduce the Risk of Type 2 Diabetes in Children

FBI
Start date: September 2006
Phase: N/A
Study type: Interventional

The purpose of this study was to determine if a family-focused lifestyle intervention helps to improve the health status, behaviors, and adjustment of overweight children.

NCT ID: NCT01145066 Completed - Diabetes Clinical Trials

Botanical Oil Supplementation in Diabetic and Metabolic Syndrome Subjects

Start date: May 2009
Phase: Phase 2
Study type: Interventional

This study will compare how well a combination of borage and echium oils will reduce inflammation compared to fish oils and placebo oil in subjects that are diabetic or have metabolic syndrome.

NCT ID: NCT01138423 Completed - Hypertension Clinical Trials

Treatment of Adiposity Related hypErTension (TARGET)

TARGET
Start date: August 2010
Phase: Phase 4
Study type: Interventional

High blood pressure (hypertension) is an important cause of myocardial infarction and stroke. High blood pressure often occurs in people who are overweight. These people frequently also have abnormal fat and sugar metabolism. The combination of these problems is called the 'metabolic syndrome'. People with hypertension and obesity currently receive the same drug therapy as people with hypertension, but without obesity. Different classes of drugs are thought to be equally effective in lowering blood pressure. Next to lowering blood pressure, hypertension treatment can have additional effects, like changes in blood vessel function (the ability to dilate and constrict) or changes is the metabolism of sugar and fat. Particularly in patients with the metabolic syndrome, these additional effects are thought to be of great importance, because they can influence the risk for cardiovascular diseases. The blood pressure lowering mechanism differs between classes of blood pressure lowering medication. The purpose of this study is to compare the effects of three types of blood pressure lowering medication belonging to different classes. The main outcomes of interest will be blood vessel function (the ability to dilate and constrict) and blood pressure. Moreover, the effect of treatment on additional outcomes, like metabolism of sugar and fat, will be studied.

NCT ID: NCT01123278 Completed - Obesity Clinical Trials

Testosterone Replacement in Metabolic Syndrome and Inflammation

TERMSINFAT
Start date: January 2004
Phase: Phase 4
Study type: Interventional

Hypogonadism (HG) frequently complicates the Metabolic Syndrome (MetS), whether testosterone replacement (TRT) is beneficial has not been clearly ascertained. This study was designed to address the effects of TRT on insulin resistance, body composition and pro-inflammatory status in naïve patients with MetS and HG.

NCT ID: NCT01120873 Completed - Metabolic Syndrome Clinical Trials

The Effect of Metamin 3D on the Lipid and Glucose in Subjects With Metabolic Syndrome

Start date: March 2007
Phase: Phase 3
Study type: Interventional

To evaluate the effect of Metamin 3D on improvement of glucose and lipid on Taiwanese subjects with metabolic syndrome.

NCT ID: NCT01119989 Completed - Metabolic Syndrome Clinical Trials

Effects of an Amino-acid Supplement on Hepatic Lipid Metabolism

AMINOFRUCT
Start date: May 2010
Phase: N/A
Study type: Interventional

10 healthy male volunteers will be studied after - a 6 day weight maintenance, balanced diet - a 6 days weight maintenance, balanced diet supplemented with 3 grams fructose/kg body weight/day - a 6 days weight maintenance, balanced diet supplemented with 3 grams fructose/kg body weight/day and 20g amino-acids per day At the end of each 6 days period, the following measurements will be obtained - intrahepatic lipids (1H-MRS) - metabolic effects of fructose ingestion (measurement of substrate oxidation, gluconeogenesis from fructose, palmitate synthesis from fructose, plasma VLDL-kinetics) This is a randomized, double blinded study

NCT ID: NCT01119690 Completed - Metabolic Syndrome Clinical Trials

Hämeenlinna Metabolic Syndrome Research Program: Effects of Rapeseed Oil on Serum Lipids and Platelet Function

HMS-03
Start date: September 2004
Phase: N/A
Study type: Interventional

In this study, the effects of dietary intake of cold-pressed turnip rapeseed oil (CTPRO) and milk fat are compared in men with metabolic syndrome having already participated in HMS-02 study.

NCT ID: NCT01115114 Completed - Clinical trials for Serious Mental Illness

Treatment of Metabolic Syndrome in a Community Mental Health Center

Start date: January 2009
Phase: N/A
Study type: Interventional

The purpose of this study is to learn if patients being treated with second generation antipsychotics and with clinically meaningful elevations/levels in any metabolic syndrome elements will have better access to medical treatment more quickly if they are randomized to one of the following conditions: 1) a primary care provider located in the community mental health center where mental health treatment is provided (IMBED), 2) a medical care manager to help coordinate treatment with an outside primary care provider (Liaison) or 3) the standard practice of advising the patient to see a primary care doctor (Treatment as Usual).

NCT ID: NCT01114763 Completed - Metabolic Syndrome Clinical Trials

Hämeenlinna Metabolic Syndrome Research Program: Oxidized LDL and Arterial Elasticity in Metabolic Syndrome and Controls (HMS-01)

HMS-01
Start date: June 2003
Phase: N/A
Study type: Observational

Mechanisms that link metabolic syndrome to atherosclerosis are incompletely understood. As a part of Hämeenlinna Metabolic Syndrome Research Program (HMS), 40 men with metabolic syndrome and their 40 physically active controls (age: 30 to 65 years) are compared in a cross-sectional study. Except routine laboratory parameters, arterial elasticity and levels of oxidized LDL are determined. Study hypothesis: Levels of oxidized LDL and findings in arterial elasticity may differ between subjects with metabolic syndrome and controls explaining the elevated risk for cardiovascular diseases among patients with metabolic syndrome.